Release Tx To Showcase Advances In Sustained Therapeutic Protein Delivery To The CNS At The 8Th CNS Drug Delivery Summit

(MENAFN- EIN Presswire)

Poster presentation to highlight latest preclinical data on the Myo-P4®, alongside the broader therapeutic potential of the Myo-P® platform

GENEVA, SWITZERLAND, November 10, 2026 /EINPresswire / -- Release Therapeutics (“Release Tx” or“the Company”), a privately held Swiss BioMedTech company, today announced that it will showcase the Myo-P^®, the Company's proprietary encapsulated cell technology (ECT) platform for sustained therapeutic protein delivery to the central nervous system (CNS), at the 8th Annual CNS Drug Delivery Summit, taking place from 1 to 3 December 2026 in Boston, Massachusetts.

Release Tx's abstract has been selected for the Summit's Scientific Poster Session, where it will be presented by Delphine Knittel, PhD, Head of Operations at Release Tx, on Wednesday, 2 December 2026 at 14:40 EST.

About the Poster Presentation:

Abstract title: 'Myo-P4, a CNS delivery system to treat Metachromatic Leukodystrophy (MLD)'

Presenting Author: Delphine Knittel, PhD, Head of Operations, Release Therapeutics SA

Date: Wednesday, 2 December 2026

Time: 14:40 EST

About the Myo-P^® Platform
The Myo-P^® is a modular encapsulated cell technology platform that combines genetically engineered, immortalised human myoblasts capable of sustained secretion of disease-specific therapeutic proteins with the Myo-Pod^®, a patented, biocompatible hollow-fibre device no larger than a pin, which has been evaluated following subdural implantation in large-animal models and subcutaneous implantation in clinical studies. Release Tx's current therapeutic focus is on rare paediatric genetic disorders affecting the CNS, with two programmes in development: the Myo-P4^® for metachromatic leukodystrophy (MLD), in collaboration with the Paris Brain Institute, and the Myo-P5A^® for Sanfilippo syndrome type IIIA (MPS IIIA), in collaboration with the University of Geneva (UNIGE).

The myoblast cell line has been engineered to produce a range of therapeutic proteins, including antibodies, enzymes and cytokines, with sustained protein secretion demonstrated in vivo for more than ten months. The Myo-Pod device is cargo-agnostic, while the broader ECT has been evaluated following subdural, subcutaneous and peritumoural implantation, supporting its potential application across multiple therapeutic areas. The Myo-P^® platform is underpinned by a long IP runway and has received external validation through publications in Cell Press journals, competitive Innosuisse funding and the 2026 Disruptive Innovation Award from Geneva University Hospitals (HUG), while research using Release Tx's licensed ECT earned researchers at HUG and the University of Geneva (UNIGE) the 2026 Pfizer Research Prize in Oncology.

About the Annual CNS Drug Delivery Summit
Organised by Hanson Wade, the annual CNS Drug Delivery Summit brings together leading experts from the pharmaceutical and biotechnology industries, academia and the investment community to explore advances in drug delivery to the central nervous system. The 2026 edition focuses on emerging technologies and strategies to overcome the blood-brain barrier, improve CNS exposure and accelerate development of next-generation therapies for neurological diseases. For more information, visit:

About Release Therapeutics
Headquartered in Geneva, Switzerland, Release Therapeutics is a privately held, BioMedTech company developing living implants to expand what is possible in the treatment of serious neurological diseases. Innovating at the nexus of Biotech and MedTech, the Company is advancing the Myo-P^®, a pioneering cell macroencapsulation platform designed to enable sustained delivery of potent therapeutic proteins beyond the human blood-brain barrier. The technology integrates implantable macroencapsulation devices with an immortalised human myoblast cell line capable of producing a broad range of proteins for long-term delivery to the central nervous system. Release Therapeutics' lead programme, the Myo-P4^®, is in preclinical development for the treatment of metachromatic leukodystrophy (MLD), a rare genetic disorder that characterised by progressive loss of myelin and which typically affects young children.

For more information, please visit our website:

Clarence Peter
Release Therapeutics SA
+41225120360 ext.
...
Visit us on social media:
LinkedIn
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

You just read:

Release Tx to Showcase Advances in Sustained Therapeutic Protein Delivery to the CNS at the 8th CNS Drug Delivery Summit News Provided By Release Therapeutics November 10, 2026, 13:30 GMT Share This Article Distribution channels: Banking, Finance & Investment Industry, Conferences & Trade Fairs, Healthcare & Pharmaceuticals Industry, Science, Technology

EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above.

MENAFN10112026003118003196ID1111941344